SB1 Alabama 2026 Session

Summary

Primary Sponsor

April WeaverSenator

Republican

Session

2026 Regular Session

Title

Controlled substances; regulate sale of nonpsychoactive consumable hemp products by Agriculture Department; require sale of products only in pharmacies; add psychoactive derivatives of hemp as Schedule I drug

Summary

SB1 would classify psychoactive hemp derivatives as Schedule I, require consumable hemp products to be derived from Alabama-grown hemp and sold only in board-certified pharmacies with testing and tracking.

What This Bill Does

It removes the hemp-exemption for psychoactive cannabinoids (like Delta-8/9/10), making them Schedule I substances in Alabama. It restricts ingestible hemp products to nonpsychoactive cannabinoids derived from hemp grown in Alabama and requires sale only through pharmacies certified by the Alabama State Board of Pharmacy, with a certificate of analysis for each product. It creates a seed-to-sale tracking system overseen by the Department of Agriculture and Industries and requires testing laboratories to be ISO/IEC 17025 accredited, linking test results to specific product batches. It repeals the previous distribution/sale restrictions from Act 2025-385 and sets phased effective dates (some provisions begin January 1, 2026; the act becomes effective July 1, 2026).

Who It Affects

• In-state consumers who buy ingestible hemp products: they would face stricter origin requirements, on-product testing, and sales limited to certified pharmacies.
• Hemp industry participants in Alabama (pharmacies, growers, processors, and testing labs): they must obtain certification, implement seed-to-sale tracking, conduct required testing, undergo inspections, and cope with associated costs.

Key Provisions

• Psychoactive cannabinoids derived from hemp (e.g., Delta-8, Delta-9, Delta-10) would be scheduled as I (not exempt as hemp-originating) and treated like other controlled substances.
• Consumbable hemp products may only contain nonpsychoactive cannabinoids derived from hemp cultivated in Alabama.
• Ingestible hemp products may be sold only by licensed pharmacies that are certified by the Alabama State Board of Pharmacy; pharmacies must maintain certificates of analysis and be subject to annual Board inspections.
• A seed-to-sale tracking system would be established by the Department of Agriculture and Industries to track cultivation, processing, testing, and sale of hemp products.
• Testing protocols would require analysis of cannabinoids, terpenes, heavy metals, pesticides, microbials, mycotoxins, solvents, and other contaminants; laboratories must be ISO/IEC 17025 accredited and able to interface with the tracking system.
• Costs for testing consumable hemp products would be borne by processors, while testing hemp plants/material would be borne by cultivators.
• The act would repeal Section 1 of Act 2025-385, which had set previous restrictions on distribution/sale and ABC Board licensing for retailers of consumable hemp products.
• Effective dates: certain provisions take effect January 1, 2026; the full act becomes effective July 1, 2026.

AI-generated summary using openai/gpt-5-nano on Feb 12, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Crimes & Offenses